BioSpect
the business of Bi
24 years of leveraging the business of Bio
www.biospectrumindia.co

STEERLife redefines potent drug development with clean, green, continuous processing

15 May 2025 | News

To lead the evolution of pharmaceutical manufacturing



Bengaluru-based STEER*Life*, the life sciences division of STEER World, is advancing the development and manufacturing of potent and complex drug products. This initiative marks a significant advancement in a field that has long been considered one of the most challenging areas within pharmaceutical science.

At the core of this advancement is STEER*Life*'s proprietary solvent-free melt fusion technology, a continuous processing system that eliminates the need for harmful organic solvents. Designed to precisely handle high-potency and hard-to-develop molecules, this platform significantly enhances formulation efficiency, safety, and scalability.

As a next-generation Contract Research, Development & Manufacturing Organization (CRDMO), STEER*Life* provides comprehensive development capabilities for complex and potent drugs - including NCEs, hormone therapies, orphan drugs, complex generics (ANDAs) and 505(b)(2) products, assisting global pharma in overcoming development and manufacturing challenges through process-driven innovation.

"Potent drug development demands more than just compliance; it requires control, care, and innovation," said Indu Bhushan, CEO & Director at STEER*Life*. "Our continuous, solvent-free platform brings all of that together - enabling faster, cleaner and more scalable development for the world's most demanding therapies."

STEER*Life* has already initiated the development of several key drug products set for market release from 2026 onwards. These include generic versions of ERLEADA® (Apalutamide), XTANDI® (Enzalutamide), VENCLEXTA® (Venetoclax), and LYNPARZA® (Olaparib), reflecting the company's ability to take on complex, high-barrier drug programs with confidence.

Working in tandem with partner facilities, STEER*Life* is strategically positioned to serve leading pharmaceutical markets across the United States, Europe, Latin America, Russia, MENA and Southeast Asia.